Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Post by Lurkylemmingon Aug 27, 2019 3:29pm
129 Views
Post# 30071584

Brutal!!

Brutal!!God Almighty what a brutal day!!  ACST continues to erode daily from its highs of a few weeks ago and the other bio I have, ATE, just announced that its critical Phase 2 results expected early September will be delayed a couple of months.  An investor in these types of companies is challenged on two fronts.  Firstly its the nature of the companies themselves always raising money, the high risk of trial failure, long timelines, management stuffing their pockets with options, etc..  Secondly is the nature of many of your fellow investors whether they are an algorithm, momentum traders, people looking to skim a few percent and move on, people with inside info, manipulators, the impatient etc...  they make the share prices so volatile.  But then big gains in these types of stocks are not realized without some severe shareholder pain I guess.  In the case of both ACST and ATE, despite current share price weakness, both stories are still intact.  I will take a position and wait for the stories to play out.  I don't know how else to best realize the potential share price appreciation of each of these companies. 
Bullboard Posts